Abstract
Since the late 1970s, local injections of BoNT have provided clinical benefit for patients with inappropriately contracting muscles with or without pain or sensory disturbance. Marketing authorization for some BoNTs, depending on country, include core indications of dystonia (blepharospasm and cervical dystonia), large muscle spastic disorders (not yet approved in the United States, e.g., adult post-stroke spasticity and equinus foot deformity), hyperhidrosis and aesthetic. Subsequent development has extended to selected conditions characterized by recurrent or chronic pain (migraine headache), and urologic indications (neurogenic/idiopathic overactive bladder; prostate hyperplasia), with multiple additional opportunities available. Portfolio management requires a careful individual opportunity assessment of scientific and technical aspects (basic science foundation, potential to treat unmet medical need, product-specific risk in specific populations, therapeutic margin/safety profile, and probability of successful registration pathway). This article describes ongoing development targets for BOTOX®.
| Original language | English |
|---|---|
| Pages (from-to) | 668-674 |
| Number of pages | 7 |
| Journal | Toxicon |
| Volume | 54 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 2009 |
| Externally published | Yes |
Keywords
- BOTOX(R)
- Benign prostatic hyperplasia
- Benign prostatic hypertrophy
- Botulinum
- Botulinum toxin
- Headache
- Migraine
- Overactive bladder